ClinicalTrials.gg
RecruitingNCT07303465Updated Dec 24, 2025

To Evaluate the Safety and Efficacy of RNK08954 in Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

A Phase 2 interventional study of RNK08954 in KRAS G12D Mutations and Pancreatic Ductal Adenocarcinoma (PDAC), sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-24.

Sponsored by Ranok Therapeutics (Hangzhou) Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is a multicenter, open-label, phase Ⅱa study to explore the safety, tolerability, and preliminary efficacy of RNK08954 in metastatic pancreatic ductal adenocarcinoma harboring a KRAS G12D mutation.

02

Conditions studied

  • KRAS G12D Mutations
  • Pancreatic Ductal Adenocarcinoma (PDAC)
03

In context

Lead sponsor

Ranok Therapeutics (Hangzhou) Co., Ltd. is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subjects voluntarily joined the study and signed the , with good compliance and follow-up.
  • Male and female subjects aged 18-75 years (including 18 and 75 years).
  • Pancreatic ductal adenocarcinoma confirmed by pathology (histology) or cytology.
  • At the time of study enrollment, according to the solid tumor efficacy evaluation criteria (RECIST1.1), imaging diagnosis had at least one .
  • Presence of a KRAS G12D mutation.
  • Physical condition score score 0-1 points.
  • Expected survival ≥ 12 weeks.
  • Have adequate hematologic and end-organ function, with laboratory test results within required parameters within 7 days prior to the first dose.
  • Fertile female subjects and male subjects whose partners are women of reproductive age must agree to comply with the requirement from the time of signing the informed consent until 6 months after the final administration of the trial drug.Fertile female subjects must undergo a serum pregnancy test within 7 days before the first dose, and the result is negative; And must be non-lactating.

Exclusion criteria

Exclusion Criteria:

  • Diagnosed with other pathological types of pancreatic tumors;
  • Presence of uncontrolled symptomatic central nervous system ; including , spinal cord metastasis, or brainstem metastasis.
  • Presence of symptomatic, moderate or greater fluid accumulation in serous cavities (e.g., pleural effusion, ascites, pericardial effusion) which either necessitates therapeutic intervention or is judged by the investigator to make the patient ineligible.
  • Clinical condition with an acute and significant decline, including, but not limited to, a decrease in performance status to >1 within 72 hours prior to the baseline visit and initiation of study treatment, a weight loss of ≥10% during the screening period, or a \<18.0 kg/m²
  • Except for certain circumstances, a history of malignant tumors other than the inclusion diagnosis within 2 years prior to the first administration of the drug;
  • History of known severe or uncontrolled cardiovascular or cerebrovascular disease that requires treatment.
  • The patient had previously used KRAS inhibitors or pan-KRAS inhibitors therapy.
  • Received systemic anti-tumor therapy prior to the first dose, or received Chinese herbal preparations with clear anti-pancreatic tumor indications within 2 weeks before the first dose.
  • Having received other drugs or therapies not yet approved for marketing prior to the first dose, with the interval from the last administration or treatment being less than 4 weeks or 5 half-lives (whichever is shorter).
  • Having undergone major surgery or experienced significant trauma within 4 weeks prior to the first dose, or requiring elective surgery during the trial period.
  • The presence of severe non-healing wounds, ulcers, fractures, etc., within 4 weeks prior to the first dose.
  • Severe infection occurred within 4 weeks prior to the first dose, including but not limited to hospitalization due to infectious complications, bacteremia, or severe pneumonia; presence of systemic active infection within 2 weeks prior to the first dose requiring systemic anti-infective therapy.
  • Presence of active tuberculosis infection at the time of screening.
  • Positive for surface antigen (HBsAg) at screening with hepatitis B virus (HBV) deoxyribonucleic acid (DNA) ≥ 2000 IU/mL or 10⁴ copies/mL (however, subjects can be enrolled if their HBV-DNA is \<2000 IU/mL or 10⁴ copies/mL after antiviral therapy).
  • Positive for antibody (HCV-Ab) and positive for hepatitis C virus (HCV) ribonucleic acid (RNA) at screening.
  • Known infection with (HIV) or active Treponema pallidum, except under certain circumstances.
  • Presence of any toxicity from previous antitumor therapies that has not recovered to Grade ≤1.
  • Other situations that the researchers believe should not be included.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    RNK08954

    Drug: RNK08954

Interventions

  • RNK08954 will be administered at the assigned dose level, orally, until disease progression or intolerable toxicity.

06

What researchers measure

Primary outcomes

  1. PFS

    Progression-free survival (PFS) is assessed by investigators using RECIST 1.1 criteria.

    Time frame: up to 2 years

Secondary outcomes

  1. ORR

    ORR was evaluated by RECIST v1.1.

    Time frame: up to 2 years

  2. DOR

    Duration of response (DoR) is assessed by investigators using RECIST 1.1 criteria.

    Time frame: up to 2 years

  3. DCR

    Disease control rate (DCR) is assessed by investigators using RECIST 1.1 criteria.

    Time frame: Up to 2 years

  4. AEs

    AEs are assessed by NCI-CTCAE v5.0

    Time frame: Up to 2 years

  5. AUC

    Area under the plasma concentration-time curve.

    Time frame: Up to 12 months

07

Study locations

2 of 2 sites recruiting
  • Nanjing Tianyinshan Hospital
    Nanjing, China
    Recruiting
  • Shanghai GoBroad Cancer Hospital China Pharmaccutical University
    Shanghai, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Nov 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2025
First posted
Dec 24, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Dec 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07303465
Lead sponsor
Ranok Therapeutics (Hangzhou) Co., Ltd.
Responsible party
Sponsor
First posted
Dec 24, 2025
Start date
Oct 14, 2025
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Dec 24, 2025

Study contacts

Xin Wu
Contact
xinwu@ranoktherapeutics.com
+86 0571 8663 0936
ShuKui Qing, MD
principal investigator · Nanjing Tianyinshan Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RNK08954

Start the discussion